EVM-16
- Generic Name
- EVM-16
FDA Clears Everest Medicines' IND Application for Novel mRNA Cancer Vaccine EVM14
• EVM14, Everest Medicines' first internally developed mRNA therapeutic vaccine, has received FDA clearance for its IND application, marking a significant milestone in the company's oncology innovation strategy.
• Preclinical studies demonstrated EVM14's ability to induce antigen-specific immune responses, inhibit tumor growth in multiple models, and prevent tumor recurrence, offering potential for long-term cancer-free survival.
• The off-the-shelf mRNA vaccine targets multiple tumor-associated antigens and is designed to treat various cancers, including non-small cell lung cancer and head and neck cancer, with plans for NMPA submission in China.
Everest Medicines Initiates First-in-Human Trial of Personalized mRNA Cancer Vaccine EVM16
• Everest Medicines has dosed the first patient with EVM16, its proprietary personalized mRNA cancer vaccine, in a first-in-human trial at Peking University Cancer Hospital in China.
• The trial will evaluate EVM16's safety, immunogenicity, and efficacy both as monotherapy and in combination with PD-1 antibody in patients with advanced or recurrent solid tumors.
• Preclinical studies demonstrated synergistic anti-tumor effects when EVM16 was combined with PD-1 antibodies, suggesting potential clinical benefits for cancer patients with limited treatment options.
Everest Medicines Advances mRNA Tumor Vaccine Pipeline Amidst Financial Growth
• Everest Medicines is focusing on mRNA-based therapeutic vaccines, with its first personalized mRNA tumor vaccine, EVM16, now in clinical trials.
• Nefecon, Everest's drug for IgA nephropathy, achieved substantial sales of 167 million yuan shortly after launch, highlighting its market potential.
• The company's financial performance is strong, with a 158% revenue increase in the first half of the year and expectations to achieve cash break-even by the end of 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath